Javascript must be enabled to continue!
Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
View through CrossRef
Background Glioblastoma (GBM) is a clinically challenging primary brain tumor with poor survival outcome despite surgical resection and intensive chemoradiation. The metabolic heterogeneity of GBM can become biomarkers for treatment response, resistance, and outcome prediction. The aim of the study is to investigate metabolic distinctions between primary and recurrent GBM tissue and patient plasma to establish feasibility for metabolic profiling. Methods A single-center cohort study analyzed tissue and blood samples from 15 patients with GBM using untargeted metabolomic/lipidomic assays. Metabolomic, lipidomic, and biogenic amine analyses were conducted on GBM tissue and patient plasma at diagnosis and recurrence using untargeted mass spectrometry. The study utilized a small but longitudinally collected cohort to evaluate alteration in metabolites, lipids, and biogenic amines between specimens at diagnosis and recurrence. Results Exploratory analysis revealed significant alteration in metabolites, lipids, and biogenic amines between diagnostic and recurrent states in both tumor and plasma specimens. Notable metabolites differed at recurrence, including N-alpha-methylhistamine, glycerol-3-phosphate, phosphocholine, and succinic acid in tissue, and indole-3-acetate, and urea in plasma. Principal component analysis revealed distinct metabolomic profiles between tumor tissue and patient plasma. Distinct metabolic profiles were observed in GBM tissue and patient plasma at recurrence, demonstrating the feasibility of using metabolomic methodologies for longitudinal studies. One patient exhibited a unique tumor resistance signature at diagnosis, possibly indicating a high-risk metabolomic phenotype. Conclusions In this small cohort, the findings suggest the potential of metabolomic signatures of GBM tissue and patient plasma for risk stratification, outcome prediction, and the development of novel adjuvant metabolic-targeting therapies. The findings suggest metabolic discrepancies at diagnosis and recurrence in tissue and plasma, highlighting potential implications for evaluation of clinical response. The identification of significant changes in metabolite abundance emphasizes the need for larger studies using targeted metabolomics to validate and further explore these profiles.
F1000 Research Ltd
Title: Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Description:
Background Glioblastoma (GBM) is a clinically challenging primary brain tumor with poor survival outcome despite surgical resection and intensive chemoradiation.
The metabolic heterogeneity of GBM can become biomarkers for treatment response, resistance, and outcome prediction.
The aim of the study is to investigate metabolic distinctions between primary and recurrent GBM tissue and patient plasma to establish feasibility for metabolic profiling.
Methods A single-center cohort study analyzed tissue and blood samples from 15 patients with GBM using untargeted metabolomic/lipidomic assays.
Metabolomic, lipidomic, and biogenic amine analyses were conducted on GBM tissue and patient plasma at diagnosis and recurrence using untargeted mass spectrometry.
The study utilized a small but longitudinally collected cohort to evaluate alteration in metabolites, lipids, and biogenic amines between specimens at diagnosis and recurrence.
Results Exploratory analysis revealed significant alteration in metabolites, lipids, and biogenic amines between diagnostic and recurrent states in both tumor and plasma specimens.
Notable metabolites differed at recurrence, including N-alpha-methylhistamine, glycerol-3-phosphate, phosphocholine, and succinic acid in tissue, and indole-3-acetate, and urea in plasma.
Principal component analysis revealed distinct metabolomic profiles between tumor tissue and patient plasma.
Distinct metabolic profiles were observed in GBM tissue and patient plasma at recurrence, demonstrating the feasibility of using metabolomic methodologies for longitudinal studies.
One patient exhibited a unique tumor resistance signature at diagnosis, possibly indicating a high-risk metabolomic phenotype.
Conclusions In this small cohort, the findings suggest the potential of metabolomic signatures of GBM tissue and patient plasma for risk stratification, outcome prediction, and the development of novel adjuvant metabolic-targeting therapies.
The findings suggest metabolic discrepancies at diagnosis and recurrence in tissue and plasma, highlighting potential implications for evaluation of clinical response.
The identification of significant changes in metabolite abundance emphasizes the need for larger studies using targeted metabolomics to validate and further explore these profiles.
Related Results
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Laboratory Model Study of Single Five-Spot and Single Injection Well Pilot Waterflooding
Laboratory Model Study of Single Five-Spot and Single Injection Well Pilot Waterflooding
Abstract
Many full-scale waterflooding operations are preceded by pilot floods, one purpose of which is to provide an estimate of recoverable oil. A laboratory mo...
Magnetohydrodynamics enhanced radio blackout mitigation system for spacecraft during planetary entries
Magnetohydrodynamics enhanced radio blackout mitigation system for spacecraft during planetary entries
(English) Spacecraft entering planetary atmospheres are enveloped by a plasma layer with high levels of ionization, caused by the extreme temperatures in the shock layer. The charg...
Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Background Glioblastoma (GBM) is a clinically challenging primary brain tumor with poor survival outcome despite surgical resection and intensive chemoradiation. The metabolic hete...
A pilot study on metabolomic characterization of human glioblastomas and patient plasma
A pilot study on metabolomic characterization of human glioblastomas and patient plasma
Abstract
Purpose
To determine whether recurrent GBMs are metabolically distinct from primary GBM, and whether patient plasma can be used as a liquid biopsy to reflect this...
Characterization of Glioblastoma by Contrast-Enhanced Flair Sequences
Characterization of Glioblastoma by Contrast-Enhanced Flair Sequences
The tissues placed on the edge of a glioblastoma's necrotic cavities are more vascularized than other pseudocystic central nervous system (CNS) tumours, both benign and malignant. ...
Differentiating brain metastasis from glioblastoma by time-dependent diffusion MRI
Differentiating brain metastasis from glioblastoma by time-dependent diffusion MRI
Abstract
Background
This study was designed to investigate the use of time-dependent diffusion magnetic resonance imaging (MRI) parameters in distin...
Abstract 2164: Overexpression of the TERT binding proteins GABPA/B in Glioblastoma
Abstract 2164: Overexpression of the TERT binding proteins GABPA/B in Glioblastoma
Abstract
Enhanced expression of TERT in gliomas is a result of two hotspot mutations, C228T and C250T, at the promoter region. GA-binding proteins selectively bind a...

